PINNACLE PHARMACEUTICALS INC
Pharmaceutical contract manufacturing and pharmaceutical services
- Sector
- UNCERTAIN
- Headquarters
- RADFORD, VA
- Latest Form D
- $8M, Jul 2011
- Total capital
- $10.3M
- Federal grants
- $2.3M
- 12 awards · 2000–2006
- 12× sector median 1 award
- Private capital raised
- $8M
- 1 Form D · last Jul 2011
- 183 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$8M
- Federal grantHealth and Human S · Phase I · Antiinfection Agents that Target Protein Synthesis$100K
- Federal grantHealth and Human S · Phase I · Potentiating compounds for aminoglycoside antiobiotics$100K
- Federal grantHealth and Human S · Phase I · Alteration of Protein Affinity$100K
- Federal grantHealth and Human S · Phase I · Potentiation of Topoisomerase I Inhibitors$100K
- Federal grantHealth and Human S · Phase I · Transcription Factor GABP as an Antitumor Target$100K
- Federal grantHealth and Human S · Phase I · Identification Of Antimicrobial Agents And Targets$100K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Identification of Antimicrobial Agents and Targets$360K
- Federal grantHealth and Human S · Phase II · Identification of Antimicrobial Agents and Targets$364K
- Federal grantHealth and Human S · Phase I · Pertubation Of Ribosomal Frameshifting$100K
- Federal grantHealth and Human S · Phase I · Rna-targeted Antimicrobial Agents$100K
- Federal grantHealth and Human S · Phase II · RNA-Targeted Antimicobial Agents$358K
- Federal grantHealth and Human S · Phase II · RNA-Targeted Antimicobial Agents$392K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
133months
from PINNACLE PHARMACEUTICALS INC’s first federal award to its first private round.
- First federal award · Jul 2000
- Health and Human S · $392K
- First Form D · Jul 2011
- $8M · 1st Form D
- Awards before first raise
- 12 awards
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Krish S. KrishnanExecutive Officer, DirectorNamed in SEC Form D filings
- Randal J. KirkDirectorNamed in SEC Form D filings
- Suma M. KrishnanExecutive OfficerNamed in SEC Form D filings
- Theodore J. FisherExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingPhenazopyridine CompoundsUSPTOApplication PCTUS2009068963
- PendingCyclodextrin Derivatives As Potentiators For AntibioticsUSPTOApplication PCTUS2008012313
- PendingAntibacterial Compounds And Uses ThereofUSPTOApplication PCTUS2006010422
Show all 5 patent records
- Phenazopyridine CompoundsApplication PCTUS2009068963Pending
- Cyclodextrin Derivatives As Potentiators For AntibioticsApplication PCTUS2008012313Pending
- Antibacterial Compounds And Uses ThereofApplication PCTUS2006010422Pending
- Parallel Identification Of Antibacterial Targets And InhibitorsApplication PCTUS2006004853Pending
- B-cyclodextrin Derivatives As Antibacterial AgentsApplication PCTUS2006002801Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .